<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Associations between pathogenic variants in established breast cancer: Predisposition genes and risk of breast cancer according to estrogen-receptor and triple-negative breast cancer status of tumors*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Associations between pathogenic variants in established breast cancer: Predisposition genes and risk of breast cancer according to estrogen-receptor and triple-negative breast cancer status of tumors*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Associations between pathogenic variants in established breast cancer: Predisposition genes and risk of breast cancer according to estrogen-receptor and triple-negative breast cancer status of tumors*</div><div class="cntnt"><table cellspacing="0"><colgroup span="7" width="14%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Breast cancer-predisposition gene</td> <td class="subtitle1" colspan="2">ER-positive breast cancer<br/> (n = 18,428)</td> <td class="subtitle1" colspan="2">ER-negative breast cancer<br/> (n = 3805)</td> <td class="subtitle1" colspan="2">Triple-negative breast cancer<br/> (n = 1463)</td> </tr> <tr> <td class="subtitle2">Participants with<br/> pathogenic variant<br/> (Number [%])</td> <td class="subtitle2">Odds ratio<br/> (95% <span style="white-space: nowrap;">CI)<sup>¶</sup></span></td> <td class="subtitle2">Participants with<br/> pathogenic variant<br/> (Number [%])</td> <td class="subtitle2">Odds ratio<br/> (95% <span style="white-space: nowrap;">CI)<sup>¶</sup></span></td> <td class="subtitle2">Participants with<br/> pathogenic variant<br/> (Number [%])</td> <td class="subtitle2">Odds ratio<br/> (95% <span style="white-space: nowrap;">CI)<sup>¶</sup></span></td> </tr> <tr> <td><em>ATM</em></td> <td class="centered">151 (0.82)</td> <td class="centered">1.96 (1.52-2.53)</td> <td class="centered">19 (0.50)</td> <td class="centered">1.04 (0.59-1.72)</td> <td class="centered">5 (0.34)</td> <td class="centered">0.50 (0.12-1.36)</td> </tr> <tr> <td><em>BARD1</em></td> <td class="centered">20 (0.11)</td> <td class="centered">0.91 (0.49-1.64)</td> <td class="centered">11 (0.29)</td> <td class="centered">2.52 (1.18-5.00)</td> <td class="centered">6 (0.41)</td> <td class="centered">3.18 (1.16-7.42)</td> </tr> <tr> <td><em>BRCA1</em></td> <td class="centered">73 (0.40)</td> <td class="centered">3.39 (2.17-5.45)</td> <td class="centered">114 (3.00)</td> <td class="centered">26.33 (17.28-41.52)</td> <td class="centered">65 (4.44)</td> <td class="centered">42.88 (26.56-71.25)</td> </tr> <tr> <td><em>BRCA2</em></td> <td class="centered">201 (1.09)</td> <td class="centered">4.66 (3.52-6.23)</td> <td class="centered">82 (2.16)</td> <td class="centered">8.89 (6.36-12.47)</td> <td class="centered">30 (2.05)</td> <td class="centered">9.70 (5.97-15.47)</td> </tr> <tr> <td><em>CDH1</em></td> <td class="centered">13 (0.07)</td> <td class="centered">3.37 (1.24-10.72)</td> <td class="centered">3 (0.08)</td> <td class="centered">N/A</td> <td class="centered">1 (0.07)</td> <td class="centered">N/A</td> </tr> <tr> <td><em>CHEK2</em></td> <td class="centered">205 (1.11)</td> <td class="centered">2.60 (2.05-3.31)</td> <td class="centered">20 (0.53)</td> <td class="centered">1.40 (0.83-2.25)</td> <td class="centered">8 (0.55)</td> <td class="centered">1.63 (0.72-3.20)</td> </tr> <tr> <td><em>NF1</em><sup>Δ</sup></td> <td class="centered">10 (0.05)</td> <td class="centered">1.63 (0.65-4.03)</td> <td class="centered">2 (0.05)</td> <td class="centered">N/A</td> <td class="centered">1 (0.07)</td> <td class="centered">N/A</td> </tr> <tr> <td><em>PALB2</em></td> <td class="centered">64 (0.35)</td> <td class="centered">3.13 (2.02-4.96)</td> <td class="centered">42 (1.10)</td> <td class="centered">9.22 (5.63-15.25)</td> <td class="centered">24 (1.64)</td> <td class="centered">13.03 (7.08-23.75)</td> </tr> <tr> <td><em>PTEN</em></td> <td class="centered">3 (0.02)</td> <td class="centered">N/A</td> <td class="centered">0</td> <td class="centered">N/A</td> <td class="centered">0</td> <td class="centered">N/A</td> </tr> <tr> <td><em>RAD51C</em></td> <td class="centered">16 (0.09)</td> <td class="centered">0.83 (0.44-1.54)</td> <td class="centered">9 (0.24)</td> <td class="centered">2.19 (0.97-4.49)</td> <td class="centered">4 (0.27)</td> <td class="centered">N/A</td> </tr> <tr> <td><em>RAD51D</em></td> <td class="centered">13 (0.07)</td> <td class="centered">1.61 (0.71-3.70)</td> <td class="centered">7 (0.18)</td> <td class="centered">3.93 (1.40-10.29)</td> <td class="centered">1 (0.07)</td> <td class="centered">N/A</td> </tr> <tr> <td><em>TP53</em><sup>Δ</sup></td> <td class="centered">9 (0.05)</td> <td class="centered">N/A</td> <td class="centered">2 (0.05)</td> <td class="centered">N/A</td> <td class="centered">2 (0.14)</td> <td class="centered">N/A</td> </tr> </tbody></table></div><div class="graphic_footnotes">ER: estrogen receptor; CI: confidence interval; <em>ATM</em>: ataxia-telangiectasia mutated; <em>BARD1</em>: <em>BRCA1</em>-associated RING domain 1; <em>BRCA1</em>: breast cancer susceptibility gene 1; <em>BRCA2</em>: breast cancer susceptibility gene 2; <em>CDH1</em>: cadherin 1; <em>CHEK2</em>: checkpoint kinase 2; <em>NF1</em>: neurofibromatosis type 1; <em>PALB2</em>: partner and localizer of <em>BRCA2</em>; <em>PTEN</em>: phosphatase and tensin homolog tumor suppressor gene; <em>RAD51C</em>: RAD51 paralog C; <em>RAD51D</em>: RAD51 paralog D; <em>TP53</em>: tumor protein p53; <font color="black">CARRIERS: Cancer Risk Estimates Related to Susceptibility Consortium; BWHS: Black Women's Health Study; CPSII: Cancer Prevention Study II; CPS3: Cancer Prevention Study-3; CTS: California Teachers' Study; MCBCS: Mayo Clinic Breast Cancer Study; MEC: Multiethnic Cohort Study; MMHS: Mayo Mammography Health Study; NHS: Nurses' Health Study; NHSII: Nurses' Health Study II; WCHS: Women's Circle of Health Study; WHI: Women's Health Initiative; WWHS: Wisconsin Women's Health Study.</font><br/>* The studies in the CARRIERS consortium that were included in this population-based analysis were BWHS, CPSII, CPS3, CTS, MCBCS, MEC, MMHS, NHS, NHSII, WCHS, WHI, and WWHS.<br/>¶ Odds ratio estimates for any breast cancer were adjusted for study, age, family history of breast cancer, and race or ethnic group.<br/>Δ Pathogenic variants in <em>NF1</em> and <em>TP53</em> were restricted to those with an alternate allele fraction between 0.3 and 0.7.</div><div class="graphic_reference">From: Hu C, Hart SN, Gnanaolivu R, et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med 2021; 384:440. Copyright © 2021 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.</div><div id="graphicVersion">Graphic 131004 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
